The Delhi HC was hearing a petition filed by Teva, which has alleged patent infringement by Natco. Copaxone is Teva's blockbuster drug with sales in the US pegged at USD 3 billion. Teva counsels had argued that Natco had earlier submitted before the court that they wouldn't export the drug to US.
The Delhi HC has stopped short of restraining Natco from exporting the generic version of Copaxone to the US.
The Delhi HC was hearing a petition filed by Teva, which has alleged patent infringement by Natco. Copaxone is Teva's blockbuster drug with sales in the US pegged at USD 3 billion. Teva counsels had argued that Natco had earlier submitted before the court that they wouldn't export the drug to US.
Also Read: Natco Pharma Q4 net profit up over 2-fold at Rs 24 cr
Teva had argued that Natco should be bound by its own statement. Teva is seeking an injunction from the Delhi HC to restrain Natco from selling the drug in the US. Natco has clarified that it has filed a review petition seeking to modify the earlier statement. The matter will now be heard on July 17.
Natco Pharma stock price
On July 08, 2014, Natco Pharma closed at Rs 1081.10, up Rs 51.00, or 4.95 percent. The 52-week high of the share was Rs 1210.70 and the 52-week low was Rs 430.00.
The company's trailing 12-month (TTM) EPS was at Rs 32.83 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 32.93. The latest book value of the company is Rs 160.81 per share. At current value, the price-to-book value of the company is 6.72.
Anda sedang membaca artikel tentang
Delhi HC doesn't stop Natco from exporting Copaxone generic
Dengan url
http://gayafashionshow.blogspot.com/2014/07/delhi-hc-doesnt-stop-natco-from.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Delhi HC doesn't stop Natco from exporting Copaxone generic
namun jangan lupa untuk meletakkan link
Delhi HC doesn't stop Natco from exporting Copaxone generic
sebagai sumbernya
0 komentar:
Posting Komentar